Immunotherapeutic targeting of Wilms' tumor protein.

Journal Article (Review)

The expression of Wilms' tumor protein (WT1)-derived peptides on malignant cell surfaces and recognition of those peptides by cellular and humoral immune responses suggest that WT1 may be a promising potential target antigen in immunotherapeutic trials. With a high frequency of expression in hematopoietic as well as solid tumors, WT1 is a broadly applicable target. Both in vivo mouse model and in vitro human studies have demonstrated the ability of WT1-specific cytotoxic T-lymphocytes to lyse WT1-expressing malignancies without harming normal tissue. WT1-peptide vaccination, in combination with adjuvants, has demonstrated the ability to activate WT1-specific immune responses and evidence of clinical activity. Because peptide-based vaccines are human leukocyte antigen-restricted, other more broadly applicable strategies are now being developed to activate WT1-specific immune responses, including the use of WT1-specific viral vectors.

Full Text

Duke Authors

Cited Authors

  • Hutchings, Y; Osada, T; Woo, CY; Clay, TM; Lyerly, HK; Morse, MA

Published Date

  • February 2007

Published In

Volume / Issue

  • 9 / 1

Start / End Page

  • 62 - 69

PubMed ID

  • 17330403

International Standard Serial Number (ISSN)

  • 1464-8431

Language

  • eng

Conference Location

  • England